Poxel 2014 Annual Results in Line with a Major Post-Closing Event: the Successful Company IPO in February 2015 Apr 30, 2015
Poxel Announces Positive Top Line Results for Its Antidiabetic Agent Imeglimin in a Phase 2b Dose-Ranging Trial Dec 17, 2014
Poxel’s Anti-diabetic Imeglimin Confirms Its Unique Mechanism of Action in Type 2 Diabetic Patients Oct 7, 2013
First Patient In for Poxel’s Imeglimin Phase IIb Monotherapy Trial to Treat Type 2 Diabetes Mar 7, 2013
